Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
|Articles|May 5, 2023
Enhance Accuracy by Eliminating Noisy Oxygen Measurements in Fermentation and Cell Culture
Author(s)Mettler-Toledo
Air and oxygen bubbles in bioreactors and fermentation vessels can cause substantial noise on signals from dissolved oxygen sensors, leading to a significant negative impact on processes. In this white paper, we examine a unique solution that eliminates DO sensor signal noise and outline a case study on the solution’s implementation.
Related to this article
InnoCare will discover compounds against up to 5 targets for Lilly, backing a deal worth up to $3.35 billion in milestones.
FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.
The FDA has approved a label update for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION data, showing a 76% reduction in clinical worsening events when added to background therapy in adults diagnosed with pulmonary arterial hypertension within the past year.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Glycomine's GLM101, an investigational liposomal mannose-1-phosphate substrate replacement therapy, has received FDA Breakthrough Therapy designation for PMM2-CDG, a rare glycosylation disorder with no approved treatments.